노인에서의 폐암치료
Treatment of lung cancer in the elderly
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Elderly patients frequently experience progressive decline of organ function and multiple comorbidities, which need to be considered when choosing therapy. In early non-small cell lung cancer (NSCLC), surgical resection is the mainstay of curative treatment with a favorable survival even in the elderly. But postoperative mortality following pneumonectomy is high, and this operation should only be performed in selected patients with acceptable heart-lung function. In locally advanced NSCLC, combined chemoradiotherapy is effective in younger patients and in older patients, despite increased toxicity. Platinum based combination chemotherapy is similar in fit older and younger patients with increased but acceptable toxicity for elderly patients. Single agent chemotherapy with a third generation agent (gemcitabine, vinorelbine, taxanes) could be considered a reasonable treatment option for elderly patients. Target therapy with pemetrexed, gefitinib and erlotinib is feasible to treat elderly patients. In limited disease small cell lung cancer (SCLC), concurrent chemoradiotherapy seem to be superior to sequential approach and yield higher survival despite increased toxicity. In case of elderly patients, it is not supported by prospective trials. Prophylactic cranial irradiation is the standard treatment in limited disease SCLC except patients with cognitive dysfunction. In extensive disease SCLC, platinum based chemotherapy is standard treatment. Many studies demonstrate that the elderly patient with a good performance status (PS) can tolerate chemotherapy that has similar toxicity and benefits as nonelderly patients. But, the assessment of comorbidity and the evaluation of functional status are prerequisite for benefit in elderly patients. It can be useful, not only for providing important information to the patients, but also for the correct choice of treatment. (Korean J Med 75:162-168, 2008)
Abstract
Elderly patients frequently experience progressive decline of organ function and multiple comorbidities, which need to be considered when choosing therapy. In early non-small cell lung cancer (NSCLC), surgical resection is the mainstay of curative treatment with a favorable survival even in the elderly. But postoperative mortality following pneumonectomy is high, and this operation should only be performed in selected patients with acceptable heart-lung function. In locally advanced NSCLC, combined chemoradiotherapy is effective in younger patients and in older patients, despite increased toxicity. Platinum based combination chemotherapy is similar in fit older and younger patients with increased but acceptable toxicity for elderly patients. Single agent chemotherapy with a third generation agent (gemcitabine, vinorelbine, taxanes) could be considered a reasonable treatment option for elderly patients. Target therapy with pemetrexed, gefitinib and erlotinib is feasible to treat elderly patients. In limited disease small cell lung cancer (SCLC), concurrent chemoradiotherapy seem to be superior to sequential approach and yield higher survival despite increased toxicity. In case of elderly patients, it is not supported by prospective trials. Prophylactic cranial irradiation is the standard treatment in limited disease SCLC except patients with cognitive dysfunction. In extensive disease SCLC, platinum based chemotherapy is standard treatment. Many studies demonstrate that the elderly patient with a good performance status (PS) can tolerate chemotherapy that has similar toxicity and benefits as nonelderly patients. But, the assessment of comorbidity and the evaluation of functional status are prerequisite for benefit in elderly patients. It can be useful, not only for providing important information to the patients, but also for the correct choice of treatment. (Korean J Med 75:162-168, 2008)
참고문헌 (39)
- 김영철, "National Survey of Lung Cancer in Korea", 2005 J Lung Cancer, 6, pp.67~73 (2007)
- Earle CC, "Potosky AL Weeks JC Who gets chemotherapy for metastatic lung cancer?", Chest, 117, pp.1239~1246 (2000)
- Yamamoto K, "Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients European", Journal of Cardio-thoracic Surgery, 23, pp.21~25 (2003)
- Cerfolio RJ, "Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study", Ann Thorac Surg, 82, pp.424~430 (2006)
- Yu HM, "Hou M Involved-field radiotherapy is effective for patients 70 years old or more with early stage non-small cell lung cancer", Radiotherapy and Oncology, 87, pp.29~34 (2008)
- Schild SE, "North Central Cancer Treatment Group. The outcome of combined-modality therapy for stage III non–smal l-cell lung cancer in the elderly", J Clin Oncol, 21, pp.3201~3206 (2003)
- Pergolizzi S, "Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions Is curative irradiation feasible?", Final results of a prospective study Lung Cancer, 37, pp.201~206 (2002)
- Semrau S, "Fietkau R Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy", Respiratory Medicine, 102, pp.210~218 (2008)
- Non-small Cell Lung Cancer Collaborative, "Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials", Br Med J, 311, pp.899~909 (1995)
- Gridelli C, "Treatment of Advanced Non–�Small-Cell Lung Cancer in the Elderly: From Best Supportive Care to the Combination of Platin-Based Chemotherapy and Targeted Therapies", Journal of Clinical Oncology, 26, pp.13~15 (2008)
- Gridelli C, "Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small cell lung cancer?", Lung Cancer, 38, pp.45~50 (2002)
- Maestu I, "Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer", Lung Cancer, 42, pp.345~354 (2003)
- Choi IS, "Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and", or weak patients with advanced non small cell lung cancer, 2003, pp.39, 99~101
- Elderly Lung Cancer Vinorelbine Italian, "Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer", J Natl Cancer Inst, 91, pp.66~72 (1999)
- Gridelli C, "Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel", J Clin Oncol, 23, pp.3125~3137 (2005)
- Nakamura Y, "Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients aged 70 years of age or older and patients under 70 years of age", Cancer Chemother Pharmacol, 46, pp.114~118 (2000)
- Fidias P, "phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer", Clin Cancer Res, 7, pp.3942~3949 (2001)
- Lilenbaum, R, "A randomized phase II trial of twoschedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer", J Thorac Oncol, 2(4), pp.306~311 (2007)
- Gridelli C, "MILES Investigators Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial", J Natl Cancer Inst, 95, pp.362~372 (2003)
- Greco FA, "Weekly docetaxel versus docetaxel", gemcitab ine in elderly, IV non-small cell lung cancer (NSCLC): Randomised phase III trial of the Minnie Pearl Cancer Research Network, pp.J Clin Oncol, 2007[DOI]
- Weiss GJ, "Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced nonsmall-cell lung cancer", J Clin Oncol, 24, pp.4405~4411 (2006)
- Merza T, "Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC)", J Clin Oncol, 25, pp.687~ (2007)
- Ramalingam SS, "Eastern Cooperative Oncology Group Outcomes for Elderly, Advanced-Stage Non–�Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599", J Clin Oncol, 26, pp.60~65 (2008)
- Fukuoka M, "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer", J Clin Oncol, 21, pp.2237~2246 (2003)
- Kris MG, "Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial", JAMA, 290, pp.2149~2158 (2003)
- Lee D, "A randomized open-label study of gefitinib versus docetaxel in patients with advanced", metastatic nonsmall cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy, 2008, pp.26, ~
- Shepherd FA, "National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non small cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
- JJackman DM, "Phase II Clinical Trial of Chemotherapy-Naı¨ve Patients _ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer", J Clin Oncol, 25, pp.760~766 (2007)
- Wheatley-Price P, "Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21", J Clin Oncol, 26, pp.2350~2357 (2008)
- Gridelli C, "Lung Cancer in the Elderly", Clin Oncol, 25, pp.1898~1907 (2007)
- De Ruysscher D, "Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer", J Clin Oncol, 24, pp.1057~1063 (2006)
- Aupérin A, "Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission", N Engl J Med, 341, pp.476~484 (1999)
- Gomez-Codina J, "Chemotherapy in small-cell lung cancer (SCLC): A randomized trial of high-dose epirubicincisplatin (HDEP) versus etoposide-cisplatin (EP)", Eur J Oncol, 35, pp.63~63 (1999)
- Ardizzoni A, "Paccagnella A Platinum-Etoposide Chemotherapy in Elderly Patients With Small-Cell Lung Cancer: Results of Randomized Multicenter Phase II Study Assessing Attenuated-Dose or Full-Dose With Lenograstim Prophylaxis—�A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAPGSTPV) Study", J Clin On, 23, pp.569~575 (2005)
- Okamoto H, "A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer", Lung Cancer, 53, pp.197~203 (2006)
- Okamoto H, "Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG) Randomized phase III trial of carboplatin(C) plus etoposide (E) vs. split doses of cisplatin (P) plus etoposide (E) in elderly or poor-risk patients with extensive disease small cell lung cancer (ED-SCLC): JCOG9702", J Clin Oncol, 23, pp.623~ (2005)
- Fried LP, "Guralnik JM Association of comorbidity with disability in older women: The women’ health and aging study", J Clin Epidemiol, 52, pp.22~37 (1999)
- Monfardini S, "Zagonel V Validation of a multidimensional scale for use in elderly cancer patients", Cancer, 77, pp.395~401 (1996)
- Extermann M, "Comorbidity and functional status are independent in older cancer patients", J Clin Oncol, 16, pp.1582~1587 (1998)